Pharming Stock Climbs on Strong Q3 Earnings Beat and Tightened Guidance

Shares in Pharming (AS: PHAR) rose 3.0% to €1.086 after the company reported third-quarter 2026 financial results that significantly surpassed analyst expectations, driven by strong sales growth from its commercial products.

Earnings Exceed Forecasts

Pharming announced a decisive beat on both its top and bottom lines for the third quarter, providing a strong company-specific catalyst for the stock's move while broader markets were largely flat. The Leiden-based firm confirmed the results in its complete financial disclosure.

Key figures from the Q3 2026 report include:

• Revenue: $117.6 million, a 21% year-over-year increase and well above the analyst consensus of approximately $103.5 million.
• Operating Profit: $29.9 million, an 89% jump from the $15.8 million reported in the same period last year.
• Net Profit: $22.4 million, nearly tripling from $7.5 million in Q3 2025, supported by higher revenue and government R&D grants.

Product Performance and Outlook

Ad

The revenue growth was fueled by strong performance from both of the company's marketed drugs. Sales of RUCONEST, a treatment for hereditary angioedema, increased 14% to $93.8 million, which the company attributed to demand stabilization and seasonal inventory building. Meanwhile, Joenja (leniolisib) saw revenues surge 58% to $23.8 million, benefiting from strong patient growth in the U.S., new launches in Germany and Japan, and an expanded pediatric label in the U.S.

Looking ahead, Pharming's management tightened its full-year 2026 revenue guidance to a range of $380 million to $390 million, narrowing it from the previous forecast of $375 million to $395 million. This move signals increased confidence in the company's performance for the remainder of the year. Investors are also watching for a near-term pipeline catalyst, with Phase II data for leniolisib in common variable immunodeficiency patients expected in November.

Market Context

The positive earnings report extends a rebound for Pharming's stock, which had been recovering from a difficult period earlier in the year that saw a CEO departure and a guidance cut. The stock's advance was driven by company-specific fundamentals, standing in contrast to a neutral backdrop from major global indices.